Fuan Pharmaceutical (300194.SZ) subsidiary has received approval for a chemical raw material drug to be listed.

16:05 26/02/2026

Fuan Pharmaceuticals (300194.SZ) announcement, the company's wholly-owned subsidiary Fuan Pharmaceuticals Group Ningbo Tianheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Tianheng Pharmaceutical") recently received the approval notice for the marketing application of the chemical raw material drug issued by the National Medical Products Administration. The raw material drug is called Metronidazole. Metronidazole is mainly used to treat infectious diseases caused by anaerobic bacteria (such as lower respiratory tract infections, pelvic inflammatory disease, sepsis, etc.).

Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Ningbo Tianheng Pharmaceutical Co., Ltd. (referred to as "Tianheng Pharmaceutical") recently received a notice of approval for the listing application of the chemical raw material drug, Metronidazole, issued by the National Medical Products Administration. Metronidazole is mainly used to treat infectious diseases caused by anaerobic bacteria (such as lower respiratory tract infections, pelvic inflammatory disease, sepsis, etc.).

PLANETREE INT'L (00613) issued 189 million shares at a price.

CF PHARMTECH (02652) spent 1.6415 million Hong Kong dollars on February 26 to repurchase 43,000 shares.

CISI FIN(06058) was granted a non-committal revolving loan financing with a maximum amount of 100 million US dollars.

PLANETREE INT'L (00613) issued 189 million shares at a price.

CF PHARMTECH (02652) spent 1.6415 million Hong Kong dollars on February 26 to repurchase 43,000 shares.

CISI FIN(06058) was granted a non-committal revolving loan financing with a maximum amount of 100 million US dollars.